[Guidelines for the management of uveitis in internal medicine]
- PMID: 18824279
- DOI: 10.1016/j.revmed.2008.08.011
[Guidelines for the management of uveitis in internal medicine]
Abstract
In developed countries, uveitis is quite common and chronic course is associated with a poor visual prognosis. However, no guidelines for their management have been consensually proposed. Based on the experience of ophthalmologists and internists from tertiary care centers, this article describes the management of uveitis, including the diagnostic procedure, indications and types of anti-inflammatory treatments. We focus on the interest of an exhaustive ophthalmologic examination for the diagnosis of an underlying systemic disease such as sarcoidosis. In this way, a multidisciplinary staff could be useful for an optimal management of uveitis. We also reviewed the main current treatments for severe uveitis. Whatever the origin of ocular inflammation, corticosteroids are consensually used as first line treatment. However, the identification of an underlying systemic disease helps in the refinement of further therapeutic choices. In cases of refractory and sight threatening uveitis, the short-term use of infliximab, a chimeric anti-TNF-alpha antibody, has been shown to be effective and safe. These recommendations do not constitute treatment guidelines but aim at improving the uniformity of clinical practice for the management of uveitis, until higher levels of evidence are obtained.
Similar articles
-
Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.Semin Arthritis Rheum. 2015 Dec;45(3):361-8. doi: 10.1016/j.semarthrit.2015.05.010. Epub 2015 May 21. Semin Arthritis Rheum. 2015. PMID: 26092330
-
Expert opinion on the use of biological therapy in non-infectious uveitis.Expert Opin Biol Ther. 2019 May;19(5):477-490. doi: 10.1080/14712598.2019.1595578. Epub 2019 Apr 16. Expert Opin Biol Ther. 2019. PMID: 30888881 Review.
-
Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.Ophthalmology. 2006 Dec;113(12):2317-23. doi: 10.1016/j.ophtha.2006.04.038. Epub 2006 Sep 25. Ophthalmology. 2006. PMID: 16996615
-
[Sarcoid uveitis: Diagnostic and therapeutic update].Rev Med Interne. 2011 Feb;32(2):86-92. doi: 10.1016/j.revmed.2010.09.003. Epub 2010 Oct 20. Rev Med Interne. 2011. PMID: 20970226 Review. French.
-
[Ocular sarcoidosis: What the internist should know?].Rev Med Interne. 2018 Sep;39(9):728-737. doi: 10.1016/j.revmed.2017.09.007. Epub 2017 Oct 14. Rev Med Interne. 2018. PMID: 29037464 Review. French.
Cited by
-
[Ocular sarcoidosis].Z Rheumatol. 2017 Jun;76(5):391-397. doi: 10.1007/s00393-017-0303-7. Z Rheumatol. 2017. PMID: 28516270 Review. German.
-
Interleukin-2 Receptor and Angiotensin-Converting Enzyme as Markers for Ocular Sarcoidosis.PLoS One. 2016 Jan 22;11(1):e0147258. doi: 10.1371/journal.pone.0147258. eCollection 2016. PLoS One. 2016. PMID: 26799486 Free PMC article.
-
Neural networks for predicting etiological diagnosis of uveitis.Eye (Lond). 2025 Apr;39(5):992-1002. doi: 10.1038/s41433-024-03530-2. Epub 2024 Dec 20. Eye (Lond). 2025. PMID: 39706896 Free PMC article.
-
Diagnosis, Classification, and Assessment of the Underlying Etiology of Uveitis by Artificial Intelligence: A Systematic Review.J Clin Med. 2023 May 29;12(11):3746. doi: 10.3390/jcm12113746. J Clin Med. 2023. PMID: 37297939 Free PMC article. Review.
-
Uveitis as an Open Window to Systemic Inflammatory Diseases.J Clin Med. 2021 Jan 14;10(2):281. doi: 10.3390/jcm10020281. J Clin Med. 2021. PMID: 33466638 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources